Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide in Chronic Hepatitis D
NCT05827146Phase 2Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of hepalatide in chronic hepatitis D (4 arms), sponsored by Shanghai Hepu Pharmaceutical. Primary endpoint: Hepatitis D Virus RNA level at Week 4. Started Oct 2023; status: completed.
02
Drugs
hepalatide
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT05827146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827146.